KIDney Injury in Times of COVID-19 (KIDCOV)

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jan 11, 2021

Keywords

ClinConnect Summary

The KIDney Injury in Times of COVID-19 (KIDCOV) trial is studying how COVID-19, even in mild or sub-clinical cases, might affect kidney health in people who are not hospitalized. Researchers want to understand if there’s a risk of kidney injury related to COVID-19, especially among different races and ethnicities. They will collect urine samples from participants in California, Michigan, and Illinois who have tested positive or negative for COVID-19. This study is important because it looks at kidney health in everyday settings and aims to gather information without requiring participants to leave their homes.

To be eligible for this trial, participants must be at least 18 years old and have had a COVID-19 test within the last four weeks. They also need to provide some basic personal information, including their race and contact details. Participants will mail in urine samples at three different times over the next year, and there is no need for any hospital visits. It's a great opportunity for those interested in contributing to important research on COVID-19 and kidney health while staying safe at home.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Result of PCR-based COVID-19 test conducted in the past 4 weeks posted in EMR of participating AMC
• • Age 18 years or older at enrollment
• • Race/ethnicity, sex, age, and phone and/or home/email address provided
• Exclusion Criteria:
• • Failure of a candidate participant to give written informed consent to comply with the study protocol
• • Hospitalization up to 4 weeks after SARS-CoV-2 test
• • History of kidney transplant
• • History of dialysis